IL307242A - Anti-CTLA-4 antibodies and methods of using them - Google Patents

Info

Publication number

IL307242A

IL307242A IL307242A IL30724223A IL307242A IL 307242 A IL307242 A IL 307242A IL 307242 A IL307242 A IL 307242A IL 30724223 A IL30724223 A IL 30724223A IL 307242 A IL307242 A IL 307242A

Authority

IL

Israel

Prior art keywords

antibody

certain embodiments

ctla

cancer

amino acid

Prior art date

2016-12-07

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title description 254
• 125000003275 alpha amino acid group Chemical group 0.000 description 267
• 206010028980 Neoplasm Diseases 0.000 description 248
• 210000004027 cell Anatomy 0.000 description 219
• 229940045513 CTLA4 antagonist Drugs 0.000 description 202
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 171
• 102000043321 human CTLA4 Human genes 0.000 description 169
• 239000008194 pharmaceutical composition Substances 0.000 description 167
• 201000011510 cancer Diseases 0.000 description 152
• 230000014509 gene expression Effects 0.000 description 122
• 239000000427 antigen Substances 0.000 description 115
• 108091007433 antigens Proteins 0.000 description 113
• 102000036639 antigens Human genes 0.000 description 113
• 230000027455 binding Effects 0.000 description 111
• 239000012634 fragment Substances 0.000 description 109
• 239000013598 vector Substances 0.000 description 93
• 102000040430 polynucleotide Human genes 0.000 description 92
• 108091033319 polynucleotide Proteins 0.000 description 92
• 239000002157 polynucleotide Substances 0.000 description 92
• 230000001394 metastastic effect Effects 0.000 description 88
• 206010061289 metastatic neoplasm Diseases 0.000 description 88
• 210000004379 membrane Anatomy 0.000 description 81
• 239000012528 membrane Substances 0.000 description 81
• 239000003814 drug Substances 0.000 description 73
• 108090000623 proteins and genes Proteins 0.000 description 64
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 57
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 57
• 238000011282 treatment Methods 0.000 description 54
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 50
• 239000000523 sample Substances 0.000 description 48
• 108010074708 B7-H1 Antigen Proteins 0.000 description 47
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 47
• 238000003745 diagnosis Methods 0.000 description 47
• 108090000765 processed proteins & peptides Proteins 0.000 description 47
• 229940124597 therapeutic agent Drugs 0.000 description 47
• 238000011275 oncology therapy Methods 0.000 description 45
• 210000004881 tumor cell Anatomy 0.000 description 43
• 230000036961 partial effect Effects 0.000 description 42
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 40
• 229910052805 deuterium Inorganic materials 0.000 description 40
• 229910052739 hydrogen Inorganic materials 0.000 description 39
• 239000001257 hydrogen Substances 0.000 description 39
• 108091008874 T cell receptors Proteins 0.000 description 38
• 230000035772 mutation Effects 0.000 description 36
• 235000018102 proteins Nutrition 0.000 description 34
• 102000004169 proteins and genes Human genes 0.000 description 34
• 235000001014 amino acid Nutrition 0.000 description 33
• 108060003951 Immunoglobulin Proteins 0.000 description 32
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 32
• 102000018358 immunoglobulin Human genes 0.000 description 32
• 238000003556 assay Methods 0.000 description 31
• 102000004196 processed proteins & peptides Human genes 0.000 description 29
• 206010008342 Cervix carcinoma Diseases 0.000 description 28
• 150000001413 amino acids Chemical class 0.000 description 28
• 201000010881 cervical cancer Diseases 0.000 description 28
• 229960005486 vaccine Drugs 0.000 description 28
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 27
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 27
• 210000004408 hybridoma Anatomy 0.000 description 27
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 27
• 238000006467 substitution reaction Methods 0.000 description 27
• 208000035473 Communicable disease Diseases 0.000 description 26
• 229940024606 amino acid Drugs 0.000 description 26
• 230000000694 effects Effects 0.000 description 26
• 239000013604 expression vector Substances 0.000 description 26
• 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 25
• 230000006044 T cell activation Effects 0.000 description 25
• 239000000203 mixture Substances 0.000 description 25
• 150000007523 nucleic acids Chemical class 0.000 description 25
• 230000001965 increasing effect Effects 0.000 description 24
• 102000039446 nucleic acids Human genes 0.000 description 24
• 108020004707 nucleic acids Proteins 0.000 description 24
• 208000015181 infectious disease Diseases 0.000 description 23
• 239000000546 pharmaceutical excipient Substances 0.000 description 23
• 239000003937 drug carrier Substances 0.000 description 22
• 230000004044 response Effects 0.000 description 22
• 206010006187 Breast cancer Diseases 0.000 description 21
• 208000026310 Breast neoplasm Diseases 0.000 description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
• 201000010106 skin squamous cell carcinoma Diseases 0.000 description 21
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 20
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 20
• 206010035226 Plasma cell myeloma Diseases 0.000 description 19
• 210000001744 T-lymphocyte Anatomy 0.000 description 19
• 238000011301 standard therapy Methods 0.000 description 19
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 18
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 18
• 125000000539 amino acid group Chemical group 0.000 description 18
• 239000005557 antagonist Substances 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 18
• 229940127089 cytotoxic agent Drugs 0.000 description 18
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 18
• 229920001184 polypeptide Polymers 0.000 description 18
• 230000009258 tissue cross reactivity Effects 0.000 description 18
• -1 wherein the antibody Proteins 0.000 description 18
• 239000002246 antineoplastic agent Substances 0.000 description 17
• 150000001875 compounds Chemical class 0.000 description 16
• 210000004602 germ cell Anatomy 0.000 description 16
• 238000010253 intravenous injection Methods 0.000 description 16
• 229960002621 pembrolizumab Drugs 0.000 description 16
• 210000000612 antigen-presenting cell Anatomy 0.000 description 15
• 238000002347 injection Methods 0.000 description 15
• 239000007924 injection Substances 0.000 description 15
• 239000003446 ligand Substances 0.000 description 15
• 230000008685 targeting Effects 0.000 description 15
• 108020004414 DNA Proteins 0.000 description 14
• 101001037141 Homo sapiens Immunoglobulin heavy variable 3-21 Proteins 0.000 description 14
• 102100040217 Immunoglobulin heavy variable 3-21 Human genes 0.000 description 14
• 239000012472 biological sample Substances 0.000 description 14
• 201000010099 disease Diseases 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 14
• 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 14
• 230000002601 intratumoral effect Effects 0.000 description 14
• 201000000050 myeloid neoplasm Diseases 0.000 description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 13
• 239000000556 agonist Substances 0.000 description 13
• 230000000890 antigenic effect Effects 0.000 description 13
• 238000005516 engineering process Methods 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 208000005017 glioblastoma Diseases 0.000 description 13
• 201000001441 melanoma Diseases 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• 108010087819 Fc receptors Proteins 0.000 description 12
• 102000009109 Fc receptors Human genes 0.000 description 12
• 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 12
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
• 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 12
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 12
• 238000009169 immunotherapy Methods 0.000 description 12
• 239000002773 nucleotide Substances 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• 210000001519 tissue Anatomy 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 11
• 208000037844 advanced solid tumor Diseases 0.000 description 11
• 238000009396 hybridization Methods 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 238000004519 manufacturing process Methods 0.000 description 11
• 238000007920 subcutaneous administration Methods 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 206010009944 Colon cancer Diseases 0.000 description 10
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 10
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 10
• 108010002350 Interleukin-2 Proteins 0.000 description 10
• 241001529936 Murinae Species 0.000 description 10
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 206010061309 Neoplasm progression Diseases 0.000 description 10
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 208000014829 head and neck neoplasm Diseases 0.000 description 10
• 230000004073 interleukin-2 production Effects 0.000 description 10
• 210000004962 mammalian cell Anatomy 0.000 description 10
• 210000003289 regulatory T cell Anatomy 0.000 description 10
• 102220259319 rs1553651734 Human genes 0.000 description 10
• 230000001988 toxicity Effects 0.000 description 10
• 231100000419 toxicity Toxicity 0.000 description 10
• 230000005751 tumor progression Effects 0.000 description 10
• 201000009030 Carcinoma Diseases 0.000 description 9
• 108091026890 Coding region Proteins 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 241000588724 Escherichia coli Species 0.000 description 9
• 102000000588 Interleukin-2 Human genes 0.000 description 9
• 239000005089 Luciferase Substances 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 9
• 206010039491 Sarcoma Diseases 0.000 description 9
• 208000003837 Second Primary Neoplasms Diseases 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 9
• 239000012636 effector Substances 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 239000001963 growth medium Substances 0.000 description 9
• 210000001165 lymph node Anatomy 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 8
• 206010001244 Adenosquamous carcinoma of the cervix Diseases 0.000 description 8
• 108060001084 Luciferase Proteins 0.000 description 8
• 206010060862 Prostate cancer Diseases 0.000 description 8
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
• 206010041848 Squamous cell carcinoma of the cervix Diseases 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 201000006662 cervical adenocarcinoma Diseases 0.000 description 8
• 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 8
• 239000002299 complementary DNA Substances 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 239000003112 inhibitor Substances 0.000 description 8
• 229960003301 nivolumab Drugs 0.000 description 8
• 238000003127 radioimmunoassay Methods 0.000 description 8
• 238000003259 recombinant expression Methods 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
• 206010033128 Ovarian cancer Diseases 0.000 description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 description 7
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
• 208000006265 Renal cell carcinoma Diseases 0.000 description 7
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 238000004422 calculation algorithm Methods 0.000 description 7
• 230000001413 cellular effect Effects 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 208000032839 leukemia Diseases 0.000 description 7
• 239000008176 lyophilized powder Substances 0.000 description 7
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
• 238000013507 mapping Methods 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 201000002528 pancreatic cancer Diseases 0.000 description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 description 7
• 229910052697 platinum Inorganic materials 0.000 description 7
• 239000007790 solid phase Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 238000007910 systemic administration Methods 0.000 description 7
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 239000012707 chemical precursor Substances 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 239000000839 emulsion Substances 0.000 description 6
• 231100000655 enterotoxin Toxicity 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 230000005714 functional activity Effects 0.000 description 6
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
• 201000010536 head and neck cancer Diseases 0.000 description 6
• 210000000987 immune system Anatomy 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 5
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
• 201000003076 Angiosarcoma Diseases 0.000 description 5
• 206010005003 Bladder cancer Diseases 0.000 description 5
• 108020004705 Codon Proteins 0.000 description 5
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
• 206010014733 Endometrial cancer Diseases 0.000 description 5
• 206010014759 Endometrial neoplasm Diseases 0.000 description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 5
• 208000032612 Glial tumor Diseases 0.000 description 5
• 206010018338 Glioma Diseases 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 208000001258 Hemangiosarcoma Diseases 0.000 description 5
• 208000017604 Hodgkin disease Diseases 0.000 description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 description 5
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 5
• 208000034578 Multiple myelomas Diseases 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 208000015634 Rectal Neoplasms Diseases 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 208000009956 adenocarcinoma Diseases 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• 229960004316 cisplatin Drugs 0.000 description 5
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 208000029742 colonic neoplasm Diseases 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 230000016396 cytokine production Effects 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
• 229960005277 gemcitabine Drugs 0.000 description 5
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
• 238000002823 phage display Methods 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000000069 prophylactic effect Effects 0.000 description 5
• 230000000306 recurrent effect Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 231100000617 superantigen Toxicity 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• 201000005112 urinary bladder cancer Diseases 0.000 description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
• 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
• 102100027581 Forkhead box protein P3 Human genes 0.000 description 4
• 101150031823 HSP70 gene Proteins 0.000 description 4
• 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 4
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 208000031888 Mycoses Diseases 0.000 description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
• 238000012408 PCR amplification Methods 0.000 description 4
• 229930012538 Paclitaxel Natural products 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 206010038389 Renal cancer Diseases 0.000 description 4
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 4
• 241000191940 Staphylococcus Species 0.000 description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 description 4
• 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 4
• 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 4
• 201000005969 Uveal melanoma Diseases 0.000 description 4
• 238000002441 X-ray diffraction Methods 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 238000012867 alanine scanning Methods 0.000 description 4
• 229960005395 cetuximab Drugs 0.000 description 4
• 238000012512 characterization method Methods 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 230000000973 chemotherapeutic effect Effects 0.000 description 4
• 239000000306 component Substances 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 101150052825 dnaK gene Proteins 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 201000003914 endometrial carcinoma Diseases 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 206010017758 gastric cancer Diseases 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 201000010982 kidney cancer Diseases 0.000 description 4
• 208000014018 liver neoplasm Diseases 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 208000021039 metastatic melanoma Diseases 0.000 description 4
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 229960001592 paclitaxel Drugs 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 230000001323 posttranslational effect Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 206010038038 rectal cancer Diseases 0.000 description 4
• 201000001275 rectum cancer Diseases 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 208000000587 small cell lung carcinoma Diseases 0.000 description 4
• 206010041823 squamous cell carcinoma Diseases 0.000 description 4
• 201000011549 stomach cancer Diseases 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 201000003120 testicular cancer Diseases 0.000 description 4
• 201000002510 thyroid cancer Diseases 0.000 description 4
• 238000004448 titration Methods 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 206010044412 transitional cell carcinoma Diseases 0.000 description 4
• 229960000575 trastuzumab Drugs 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 3
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 3
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 3
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
• 208000003950 B-cell lymphoma Diseases 0.000 description 3
• 208000035143 Bacterial infection Diseases 0.000 description 3
• 206010004146 Basal cell carcinoma Diseases 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
• 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 3
• 101100451497 Dictyostelium discoideum hspB gene Proteins 0.000 description 3
• 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• 101150022862 HSC70 gene Proteins 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 3
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
• 208000030852 Parasitic disease Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108091027981 Response element Proteins 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 3
• 206010041067 Small cell lung cancer Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 206010057644 Testis cancer Diseases 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 208000002495 Uterine Neoplasms Diseases 0.000 description 3
• 230000000692 anti-sense effect Effects 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 229960000397 bevacizumab Drugs 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 239000002738 chelating agent Substances 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000003501 co-culture Methods 0.000 description 3
• 238000012875 competitive assay Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 238000010494 dissociation reaction Methods 0.000 description 3
• 230000005593 dissociations Effects 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 210000001671 embryonic stem cell Anatomy 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 229950006370 epacadostat Drugs 0.000 description 3
• 201000004101 esophageal cancer Diseases 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 230000002440 hepatic effect Effects 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 229950009034 indoximod Drugs 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 238000012004 kinetic exclusion assay Methods 0.000 description 3
• KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 3
• 201000007270 liver cancer Diseases 0.000 description 3
• 238000003468 luciferase reporter gene assay Methods 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 208000037819 metastatic cancer Diseases 0.000 description 3
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
• 208000037843 metastatic solid tumor Diseases 0.000 description 3
• 230000001338 necrotic effect Effects 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 229940043131 pyroglutamate Drugs 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 238000002864 sequence alignment Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 238000011521 systemic chemotherapy Methods 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 229960001612 trastuzumab emtansine Drugs 0.000 description 3
• 206010046766 uterine cancer Diseases 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 238000012815 AlphaLISA Methods 0.000 description 2
• 208000007860 Anus Neoplasms Diseases 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006143 Brain stem glioma Diseases 0.000 description 2
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
• 102100029968 Calreticulin Human genes 0.000 description 2
• 108090000549 Calreticulin Proteins 0.000 description 2
• 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 2
• 241000606161 Chlamydia Species 0.000 description 2
• 208000005243 Chondrosarcoma Diseases 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000194032 Enterococcus faecalis Species 0.000 description 2
• 208000006168 Ewing Sarcoma Diseases 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 208000009889 Herpes Simplex Diseases 0.000 description 2
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
• 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 108010073807 IgG Receptors Proteins 0.000 description 2
• 102000009490 IgG Receptors Human genes 0.000 description 2
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 2
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 2
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
• 241000588747 Klebsiella pneumoniae Species 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
• 206010027406 Mesothelioma Diseases 0.000 description 2
• 208000032818 Microsatellite Instability Diseases 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 241000588767 Proteus vulgaris Species 0.000 description 2
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 241000606701 Rickettsia Species 0.000 description 2
• 239000008156 Ringer's lactate solution Substances 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 2
• 206010061934 Salivary gland cancer Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229940126530 T cell activator Drugs 0.000 description 2
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
• 206010053461 Trichosporon infection Diseases 0.000 description 2
• 208000007501 Trichosporonosis Diseases 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
• 241000700647 Variola virus Species 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 206010047741 Vulval cancer Diseases 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 230000033289 adaptive immune response Effects 0.000 description 2
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 239000008135 aqueous vehicle Substances 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229960000686 benzalkonium chloride Drugs 0.000 description 2
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
• 229960001950 benzethonium chloride Drugs 0.000 description 2
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
• AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 201000000053 blastoma Diseases 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 201000003984 candidiasis Diseases 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 190000008236 carboplatin Chemical compound 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000012411 cloning technique Methods 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 239000008355 dextrose injection Substances 0.000 description 2
• 238000002050 diffraction method Methods 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 210000003162 effector t lymphocyte Anatomy 0.000 description 2
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
• 201000008184 embryoma Diseases 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 229940032049 enterococcus faecalis Drugs 0.000 description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• 210000003236 esophagogastric junction Anatomy 0.000 description 2
• 235000019441 ethanol Nutrition 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 238000002825 functional assay Methods 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• 229960002584 gefitinib Drugs 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229940022353 herceptin Drugs 0.000 description 2
• 102000054189 human CD80 Human genes 0.000 description 2
• 102000049849 human CD86 Human genes 0.000 description 2
• 102000048362 human PDCD1 Human genes 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000008629 immune suppression Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 239000012678 infectious agent Substances 0.000 description 2
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 208000022013 kidney Wilms tumor Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 238000004811 liquid chromatography Methods 0.000 description 2
• 239000003589 local anesthetic agent Substances 0.000 description 2
• 229960005015 local anesthetics Drugs 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 208000026037 malignant tumor of neck Diseases 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 238000012900 molecular simulation Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 238000002515 oligonucleotide synthesis Methods 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 229960005079 pemetrexed Drugs 0.000 description 2
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
• AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 229940007042 proteus vulgaris Drugs 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 201000003233 renal Wilms' tumor Diseases 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 239000003352 sequestering agent Substances 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 208000017572 squamous cell neoplasm Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000011146 sterile filtration Methods 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
• 208000023747 urothelial carcinoma Diseases 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 201000005102 vulva cancer Diseases 0.000 description 2
• 238000002424 x-ray crystallography Methods 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• ALEVUYMOJKJJSA-UHFFFAOYSA-N 4-hydroxy-2-propylbenzoic acid Chemical class CCCC1=CC(O)=CC=C1C(O)=O ALEVUYMOJKJJSA-UHFFFAOYSA-N 0.000 description 1
• UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 239000012114 Alexa Fluor 647 Substances 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241001225321 Aspergillus fumigatus Species 0.000 description 1
• 208000036641 Aspergillus infections Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 229940125565 BMS-986016 Drugs 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000589969 Borreliella burgdorferi Species 0.000 description 1
• 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
• 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 101100124795 Caenorhabditis elegans hsp-110 gene Proteins 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 206010007134 Candida infections Diseases 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• 102000047934 Caspase-3/7 Human genes 0.000 description 1
• 108700037887 Caspase-3/7 Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 101150015280 Cel gene Proteins 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000006303 Chaperonin 60 Human genes 0.000 description 1
• 108010058432 Chaperonin 60 Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 241001502567 Chikungunya virus Species 0.000 description 1
• 241000195585 Chlamydomonas Species 0.000 description 1
• 241000195628 Chlorophyta Species 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000003495 Coccidiosis Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241001040637 Curvularia geniculata Species 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 208000001490 Dengue Diseases 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• 206010012504 Dermatophytosis Diseases 0.000 description 1
• 206010072449 Desmoplastic melanoma Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 241001466953 Echovirus Species 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 208000000088 Enchondromatosis Diseases 0.000 description 1
• 101710146739 Enterotoxin Proteins 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 235000014966 Eragrostis abyssinica Nutrition 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 208000014260 Fungal keratitis Diseases 0.000 description 1
• 206010061138 Fungal peritonitis Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000223218 Fusarium Species 0.000 description 1
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
• 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
• 101100061678 Homo sapiens CTLA4 gene Proteins 0.000 description 1
• 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 1
• 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 201000000512 Intraocular Lymphoma Diseases 0.000 description 1
• 206010023076 Isosporiasis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 241001466978 Kyasanur forest disease virus Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 101150030213 Lag3 gene Proteins 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
• 206010027260 Meningitis viral Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010059282 Metastases to central nervous system Diseases 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
• 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 1
• 241001460074 Microsporum distortum Species 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 208000026616 Ollier disease Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010050346 Oropharyngeal candidiasis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 206010033767 Paracoccidioides infections Diseases 0.000 description 1
• 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
• 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
• 241000710884 Powassan virus Species 0.000 description 1
• HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 206010037075 Protozoal infections Diseases 0.000 description 1
• 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
• 208000006257 Rinderpest Diseases 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 108010086229 SYN-004 Proteins 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 241000242678 Schistosoma Species 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 206010041736 Sporotrichosis Diseases 0.000 description 1
• 206010041849 Squamous cell carcinoma of the hypopharynx Diseases 0.000 description 1
• 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
• 208000035518 Squamous cell carcinoma of the oropharynx Diseases 0.000 description 1
• 241000710888 St. Louis encephalitis virus Species 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010042938 Systemic candida Diseases 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
• 208000002474 Tinea Diseases 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 201000003761 Vaginal carcinoma Diseases 0.000 description 1
• 206010046914 Vaginal infection Diseases 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
• 241000710886 West Nile virus Species 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000027024 X-linked chronic granulomatous disease Diseases 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 241000710772 Yellow fever virus Species 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• 241000907316 Zika virus Species 0.000 description 1
• 206010061418 Zygomycosis Diseases 0.000 description 1
• 241000222126 [Candida] glabrata Species 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 229940008421 amivantamab Drugs 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000000507 anthelmentic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000000611 antibody drug conjugate Substances 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 229940049595 antibody-drug conjugate Drugs 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 229940121357 antivirals Drugs 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 239000010425 asbestos Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 229940091771 aspergillus fumigatus Drugs 0.000 description 1
• 208000005012 aspergillus niger infection Diseases 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 229960003852 atezolizumab Drugs 0.000 description 1
• 229950002916 avelumab Drugs 0.000 description 1
• KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 238000010009 beating Methods 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 201000007180 bile duct carcinoma Diseases 0.000 description 1
• 201000009036 biliary tract cancer Diseases 0.000 description 1
• 208000020790 biliary tract neoplasm Diseases 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 201000000220 brain stem cancer Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 208000032343 candida glabrata infection Diseases 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 230000014564 chemokine production Effects 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000036733 chronic X-linked granulomatous disease Diseases 0.000 description 1
• 208000016532 chronic granulomatous disease Diseases 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 239000000562 conjugate Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 150000001896 cresols Chemical class 0.000 description 1
• 208000005035 cutaneous candidiasis Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 208000025729 dengue disease Diseases 0.000 description 1
• 238000010217 densitometric analysis Methods 0.000 description 1
• 229950002756 depatuxizumab Drugs 0.000 description 1
• 229950008925 depatuxizumab mafodotin Drugs 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000013154 diagnostic monitoring Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 208000019164 disseminated candidiasis Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 229950009791 durvalumab Drugs 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 201000000330 endometrial stromal sarcoma Diseases 0.000 description 1
• 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 1
• 206010014801 endophthalmitis Diseases 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000000147 enterotoxin Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 229950008579 ertumaxomab Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 231100000573 exposure to toxins Toxicity 0.000 description 1
• 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 230000001408 fungistatic effect Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 201000006974 gastroesophageal cancer Diseases 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 230000007946 glucose deprivation Effects 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 208000010710 hepatitis C virus infection Diseases 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 102000053464 human BTLA Human genes 0.000 description 1
• 102000043396 human ICOS Human genes 0.000 description 1
• 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 239000007946 hypodermic tablet Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 229950005646 imgatuzumab Drugs 0.000 description 1
• 230000000899 immune system response Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 208000037798 influenza B Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000002664 inhalation therapy Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 230000006662 intracellular pathway Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 229950010897 iproplatin Drugs 0.000 description 1
• 230000002262 irrigation Effects 0.000 description 1
• 238000003973 irrigation Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229950010860 laprituximab emtansine Drugs 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 201000005640 larynx verrucous carcinoma Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229950003135 margetuximab Drugs 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 201000008749 mast-cell sarcoma Diseases 0.000 description 1
• 208000004396 mastitis Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 229950008001 matuzumab Drugs 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 201000011475 meningoencephalitis Diseases 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 239000002184 metal Chemical class 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 201000006894 monocytic leukemia Diseases 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 201000007524 mucormycosis Diseases 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 210000004296 naive t lymphocyte Anatomy 0.000 description 1
• 229960000513 necitumumab Drugs 0.000 description 1
• 229950007221 nedaplatin Drugs 0.000 description 1
• 230000007302 negative regulation of cytokine production Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229950010203 nimotuzumab Drugs 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 101710135378 pH 6 antigen Proteins 0.000 description 1
• 238000010979 pH adjustment Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 201000002523 pancreas lymphoma Diseases 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 210000003695 paranasal sinus Anatomy 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000029255 peripheral nervous system cancer Diseases 0.000 description 1
• 229960002087 pertuzumab Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229950005566 picoplatin Drugs 0.000 description 1
• IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 201000000317 pneumocystosis Diseases 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 229960001309 procaine hydrochloride Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 208000028172 protozoa infectious disease Diseases 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229910052895 riebeckite Inorganic materials 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 201000003804 salivary gland carcinoma Diseases 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 208000019694 serous adenocarcinoma Diseases 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 201000000307 small intestine lymphoma Diseases 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229960004249 sodium acetate Drugs 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000008137 solubility enhancer Substances 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 229940035044 sorbitan monolaurate Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 229950007213 spartalizumab Drugs 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000013066 thyroid gland cancer Diseases 0.000 description 1
• 201000004647 tinea pedis Diseases 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 229940049679 trastuzumab deruxtecan Drugs 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• 201000010044 viral meningitis Diseases 0.000 description 1
• 229960004854 viral vaccine Drugs 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 208000013013 vulvar carcinoma Diseases 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000008136 water-miscible vehicle Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 229940051021 yellow-fever virus Drugs 0.000 description 1
• 229950008250 zalutumumab Drugs 0.000 description 1